T
Tenpoint Therapeutics
Ophthalmic therapies for aging eye conditions
About Tenpoint Therapeutics
TenPoint Therapeutics is a pioneering startup operating in the healthcare sector, specifically focusing on ocular diseases. The company is at the forefront of a revolution in the treatment of eye diseases, leveraging the potential of regenerative therapies to restore sight. Their approach involves the development of engineered cell-based therapeutics and in vivo reprogramming to reverse vision loss caused by the deterioration of functional tissue in the eye.
Read full description
The company's unique selling proposition lies in its innovative use of the eye's properties, which make it an ideal setting for their therapeutic approach. TenPoint Therapeutics employs new techniques to replace lost or damaged cells, potentially restoring their function with a single, long-lasting treatment that reverses the course of disease.
The startup's business model revolves around the development and commercialization of these regenerative therapies. Their target market includes patients suffering from various ocular diseases, with the potential to significantly improve their quality of life.
The company was founded by experts from leading institutions in ocular disease, including Moorfields Eye Hospital, UCL Institute of Ophthalmology, Institut de la Vision, and the University of Washington. This gives them a strong foundation in terms of expertise and access to advancements in regenerative biology technologies.
In terms of revenue generation, it can be inferred that the company aims to make money by selling their therapeutic solutions to healthcare providers or directly to patients, although the specifics of their revenue model are not explicitly stated.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- London, United Kingdom
- Employees
- 79
- Open positions
- 15
- Dealroom signal
- 93.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Ophthalmology, Eye Diseases, Spinout, Digital Therapeutics, Biotech and Pharma, DT and LS, uk is8 life sciences, UKSU
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Dec 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Jan 2026 | $150M | — | Hercules Capital | ↗ |
| SERIES BOther financing | Jan 2026 | $85M | $340M | Sofinnova Partners · EQT Life Sciences · F-Prime · Hillhouse Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Tenpoint Therapeutics is 3.7K monthly website visits, up 32.1% over the last three months. Tenpoint Therapeutics's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A14 investors entered at this stage
UCL Technology Fund
AlbionVC
British Patient Capital
Qiming Venture Partners USA
Eight Roads Ventures
Sofinnova Partners
F-Prime
Hillhouse Capital
British Business Bank
EQT Group
Janus Henderson Investors
EQT Life Sciences
AdBio partners
Wille Finance
Series B and later1 investor entered at this stage
Hercules Capital
Other known investors1 additional known investor
University College London
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tenpoint Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tenpoint Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.